Rinvoq
Rinvoq ingredients
| Active ingredient | Strength |
|---|---|
| Upadacitinib | 1 mg/mL, 45 mg/1, 30 mg/1, 15 mg/1 |
What Rinvoq is used for
The FDA lists the approved uses on the official label (below). In the EU, upadacitinib is approved as Rinvoq for:
Rheumatoid arthritis Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate. Psoriatic arthritis Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Rinvoq may be used as monotherapy or in combination with methotrexate. Polyarticular juvenile idiopathic arthritis Rinvoq is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients 2 years of age and older who have responded inadequately to, or who are intoleran…
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rinvoq
- Generic name
- Upadacitinib
- Made by
- AbbVie Inc.
- Forms
- Solution, Tablet, Extended Release
- Given
- Oral
- Drug class
- Janus Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA218347
- On the US market since
- 2019
Official information
- Rinvoq prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Upadacitinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rinvoq?
Rinvoq (Upadacitinib) is a cancer medicine made by AbbVie Inc., approved by the US FDA.
What are the ingredients of Rinvoq?
Rinvoq contains Upadacitinib (1 mg/mL, 45 mg/1, 30 mg/1, 15 mg/1).
Is Rinvoq approved in Europe?
The same active substance is approved in the EU as Rinvoq.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA